Resistance in Hematologic Malignancies and Cancer
- 1st Edition - October 29, 2024
- Imprint: Academic Press
- Editors: Lucia Messingerova, Albert Breier
- Language: English
- Hardback ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 0 - 6
- eBook ISBN:9 7 8 - 0 - 4 4 3 - 2 1 7 9 1 - 3
Resistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment… Read more
Purchase options
Institutional subscription on ScienceDirect
Request a sales quoteResistance in Hematologic Malignancies and Cancer brings together the molecular, cellular, and biochemical basis/principles of various mechanisms of resistance to treatment in hematologic malignancies.
Even though main mechanisms of resistance are the same in different types of tumours there are specific signalling pathways involved in resistance in hematological malignancies and of course specific treatments
In 11 chapters, Resistance in Hematologic Malignancies and Cancer describes the development of treatment resistance in hematological malignancies, the role of MiRNA in resistance, the role of the immune system in resistance prediction, as well as the latest knowledge from clinical research.
It gives insight in the complex information about different mechanisms linkage in final loss of cell sensitivity to drug treatment, the orientation in metabolic pathways that could be involved in depressed leukemia cell resistance to drugs and gives information about causes of drug resistance in leukemia cells.
By the multidisciplinary approach of the processing this book is a valuable resource for both health professionals, scientists and researchers, health practitioners, students, but will also enable members of the general professional public to orientate themselves in issues that are not directly in their area of expertise
- Describes the different mechanisms of resistance; cooperation in net resistance to antileukemic drugs
- Provides hallmark information about cell regulation pathways in drug resistance development
- Brings information about causes of drug resistance in leukemia and hematologic malignancies including lymphoma and myeloma
Researchers and graduate students in cancer research Medical oncologist and Pharmacologist. Clinical researchers, Undergraduate and postgraduate courses in medicine, biochemistry, pharmacy, biology
1. Drug classification for treatment Hematological Malignancies
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates – obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
2. Reduce drug uptake in development of resistance
3. The Role of Enhanced Drug Efflux in Drug Resistance
4. MicroRNAs and other non-coding RNA species in diagnostics, prognostics and therapy response of blood cancers.
5. Switching between autophagy and apoptosis pro-survival and pro-death balance in leukemia cells
6. The role of UPR signaling pathways in cancer cell resistance to chemotherapy
7. Altered cell cycle regulation
8. Deregulation of drug metabolizing enzymes and transporters in cancer via the aryl hydrocarbon receptor
9. Immune system in resistance prediction
10. Mechanisms of resistance of antibody-drug conjugates – obstacles to overcome
11. Resistance to Chimeric Antigen Receptor T Cells (CAR-T)
- Edition: 1
- Published: October 29, 2024
- No. of pages (Hardback): 326
- Imprint: Academic Press
- Language: English
- Hardback ISBN: 9780443217906
- eBook ISBN: 9780443217913
LM
Lucia Messingerova
After completing her studies, Dr. Messingerova started working at the Slovak Technical University, Faculty of Chemical and Food Technology, as well as at the Slovak Academy of Sciences in the Centre for Biosciences, where she leads a team dealing with the development of resistance to hypomethylating agents (HMAs) in patients with myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). In her work, she focuses on changes in apoptotic pathways, transport, and metabolism of HMAs in sensitive and resistant AML cell lines. The goal of her team's work is to identify an easily and quickly detectable marker of response to HMA treatment, since it is known that after the failure of this treatment in patients unsuitable for intensive therapy, only the possibility of inclusion in clinical trials or palliative care remains.
Affiliations and expertise
Slovak Academy of Sciences, Centre of Bioscineces, Institute of Molecular Physiology and Genetics, Bratislava, SlovakiaAB
Albert Breier
Albert Breier is Professor at the Faculty of Chemical and Food Technology, Slovak University of Technology, and Chief Research fellow at the Institute of Molecular Physiology and Genetics, Centre of Biosciences, Slovak Academy of Sciences, Bratislava, Slovak Republic, Chief Research Fellow. He holds a PhD in Biochemistry and is the author of more than 130 scientific publications that were more than 1200 times cited. His research interest is anti-cancer agents
Affiliations and expertise
Head of Biochemistry and Microbiology Department, Faculty of Chemical and Food Technology, Slovak University of Technology, Bratislava, SlovakiaRead Resistance in Hematologic Malignancies and Cancer on ScienceDirect